Can’t verify that all of the following was attributable to just Karen but I am hopeful she was instrumental in some of these achievements with her previous employer.
Soligenix Appoints Karen Krumeich, asChief Financial Officer
Published:Jun 20, 2016
PRINCETON,N.J., June 20, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Karen Krumeich, as its Senior Vice President and Chief Financial Officer. Ms. Krumeich has over 25 years of diverse experience in the financial and strategic management of emerging growth life science companies. She has a proven track record and expertise in corporate financial operations, equity financings, and business development, including partnerships, mergers and acquisitions.
ACHIEVEMENTS (after appointment)
Sep 12, 2016 - Soligenix andSciClone Establish Regional Licensing Agreement for SGX942, a Novel ProductCandidate for Oral Mucositis
Oct 25, 2016 - SoligenixReceives European Medicines Agency Designation as Small and Medium Enterprise
Dec 20, 2016 - SoligenixAdvances Collaboration with IDT Biologika
Jan 3, 2017 - SoligenixAnnounces Extension of Development Agreement with Emergent BioSolutions
Sep 13, 2018 - NIH selectsSoligenix’s SGX942 in the Treatment of Oral Mucositis for the CommercializationAccelerator Program
